Peritoneal Cancer Market Outlook 2025-2035: The 7 major Peritoneal Cancer Market are expected to exhibit a CAGR of 18.7% during 2025-2035. The peritoneal cancer market is growing, as people become ...

Gastric adenocarcinoma is the fourth most common cancer and the second leading cause of cancer-related mortality worldwide ... patients have unresectable disease upon diagnosis (4). Peritoneal ...

Dizziness has many possible causes, which may relate to a person’s external environment, the medications they take, or an underlying condition. Dizziness refers to a range of sensations ...

The process of metabolization, while essential, can cause progressive damage to cells, a phenomenon referred to as metabolic aging. Some experts believe that slowing down the metabolic process through ...

Get Instant Summarized Text (Gist) Chemotherapy is linked to chronic peripheral neuropathy in over 40% of patients, with platinum-based drugs, taxanes, and lung cancer showing the highest rates ...

In 2022, more than 941,600 Americans died from cardiovascular disease. Heart disease remains the leading cause of death in the United States, according to a new report. The American Heart ...

Nelmastobart (hSTC810) combined with capecitabine therapy in metastatic colorectal cancer with resistance or intolerance to oxaliplatin and irinotecan-based chemotherapy: A phase 1b clinical trial.

The Central Intelligence Agency said the Covid-19 pandemic “more likely” originated from a lab leak than a natural source, shifting its stance after previously saying both scenarios were ...

Possible causes of low blood pressure, or hypotension, range from dehydration to a heart condition. Drinking more water may help, but some people will need medication. Changing dietary habits may ...

Tulmimetostat is under clinical development by MorphoSys and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I drugs for Peritoneal Cancer have an 85% phase transition ...

Nesuparib is under clinical development by Onconic Therapeutics and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase ...